What is Chardan Capital’s Estimate for LXEO FY2025 Earnings?

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Stock analysts at Chardan Capital boosted their FY2025 EPS estimates for shares of Lexeo Therapeutics in a research report issued on Tuesday, April 8th. Chardan Capital analyst G. Livshits now expects that the company will post earnings of ($3.06) per share for the year, up from their previous estimate of ($3.10). Chardan Capital currently has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09.

LXEO has been the subject of a number of other research reports. Leerink Partners decreased their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Monday, March 24th. HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday. Finally, Royal Bank of Canada lowered their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 25th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Lexeo Therapeutics presently has a consensus rating of “Buy” and an average price target of $22.20.

Lexeo Therapeutics Price Performance

Lexeo Therapeutics stock opened at $2.17 on Friday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $72.04 million, a P/E ratio of -0.69 and a beta of 1.52. The business has a 50-day moving average of $3.40 and a 200-day moving average of $6.02. Lexeo Therapeutics has a 1 year low of $1.45 and a 1 year high of $19.50.

Hedge Funds Weigh In On Lexeo Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC grew its holdings in Lexeo Therapeutics by 15.3% during the fourth quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company’s stock worth $28,508,000 after purchasing an additional 576,059 shares during the period. Altium Capital Management LLC bought a new position in shares of Lexeo Therapeutics during the fourth quarter worth approximately $2,665,000. Point72 Asset Management L.P. lifted its holdings in Lexeo Therapeutics by 102.5% during the 4th quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company’s stock worth $4,937,000 after purchasing an additional 379,828 shares during the last quarter. Vestal Point Capital LP boosted its stake in Lexeo Therapeutics by 41.2% in the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock valued at $7,896,000 after purchasing an additional 350,000 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Lexeo Therapeutics by 86.5% in the 3rd quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock valued at $5,003,000 after buying an additional 256,635 shares in the last quarter. 60.67% of the stock is owned by institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.